Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LongRiver Investments is a venture capital firm founded in 2022 by Graham Rhodes, based in Hong Kong. The firm focuses on global equity strategies, utilizing local networks and insights from Asia to identify exceptional, typically founder-led businesses. LongRiver Investments operates with a disciplined value investing approach, emphasizing a margin of safety in its investment strategy.
As of 2026, LongRiver manages approximately $400 million in assets under management (AUM) and has closed its debut fund at $385 million. The firm primarily serves Professional Investors as defined under the Securities and Futures Ordinance in Hong Kong. LongRiver has established a presence in multiple locations, including Hong Kong and Shanghai, and is expanding its global footprint.
Notable milestones include the planned acquisition of portfolio company Ouro Medicines by Gilead Sciences, which highlights the firm’s capability in identifying high-potential investments. LongRiver Investments is committed to supporting its portfolio companies throughout the full investment cycle, from sourcing to exit.
LongRiver Investments targets investments in healthcare, biotechnology, deep tech, and artificial intelligence. The firm focuses on seed, Series A, Series B, and growth equity stages, primarily in Europe and the United States. LongRiver seeks to back a small number of businesses that demonstrate the potential for compounding growth over time.
The firm employs a value investing approach, emphasizing a disciplined strategy that seeks a margin of safety. LongRiver's investment thesis is centered on identifying future sector leaders in healthcare and technology, leveraging global capital and domain expertise. The firm collaborates with industry leaders and key opinion leaders to enhance its portfolio companies' growth potential.
LongRiver's investment strategy includes a focus on capital-efficient, founder-led businesses. The firm values strong management teams and innovative solutions that address significant market needs. LongRiver's cross-border networks facilitate access to resources and expertise, enhancing the growth trajectory of its portfolio companies.
LongRiver Investments has a diverse portfolio that includes:
This portfolio reflects LongRiver's commitment to investing in innovative healthcare and technology companies with strong growth potential.
Graham Rhodes: Founder of LongRiver Investments, Graham has extensive experience in investment management and has established the firm to focus on global equity strategies.
Jiang Zhang: Founder & Chief Executive Officer. Jiang previously served as the founding partner and former CEO of Ping An Ventures, managing multiple RMB and USD funds.
Dr. Jerry Wu: Managing Director, Dr. Wu is a key contact for LongRiver in Hong Kong, bringing significant expertise in venture capital.
Maxine Kexin Zhou: Head of Investor Relations, Maxine oversees investor communications and relations, ensuring alignment between the firm and its investors.
Sophia Dong: Venture Capital Investment Associate, Sophia supports the investment team in evaluating potential portfolio companies and managing existing investments.
To pitch LongRiver Investments, founders should use the contact email info@lr-investments.com or visit their website at lr-investments.com. While specific details regarding the pitch process are not disclosed, it is advisable to include a clear overview of the business model, market opportunity, and management team in the pitch deck.
Founders should be prepared for a potentially lengthy decision timeline, as the firm emphasizes a disciplined investment strategy. Warm introductions may enhance the chances of receiving a timely response.
In March 2026, LongRiver Investments announced the planned acquisition of portfolio company Ouro Medicines by Gilead Sciences, valued at up to $2.175 billion. This acquisition highlights the firm's ability to identify high-potential investments in the biotechnology sector.
Additionally, LongRiver made several investments in March 2026, including seed investments in OpenJobs AI and Flowith, alongside Fengshion Capital and HongShan, respectively. These investments reflect the firm's ongoing commitment to supporting innovative companies in the healthcare and technology sectors.
What are LongRiver Investments' primary investment criteria?
LongRiver Investments focuses on healthcare, biotechnology, deep tech, and AI sectors. The firm targets seed to growth equity stages and seeks capital-efficient, founder-led businesses with strong management teams.
How can I pitch to LongRiver Investments?
Founders can pitch to LongRiver Investments via their website at lr-investments.com or by emailing info@lr-investments.com. Specific details regarding the pitch process are not disclosed.
What makes LongRiver Investments different from other VC firms?
LongRiver emphasizes a value investing approach, focusing on a disciplined investment strategy that seeks a margin of safety. The firm leverages its global resources and cross-border networks to support portfolio companies throughout the investment cycle.
What is the geographic focus of LongRiver Investments?
The firm primarily invests in Europe and the United States, with a particular interest in companies that have a connection to Greater China.
What is the typical check size for investments?
Specific check sizes are not disclosed, but LongRiver targets seed to growth equity stages, indicating a range of investment amounts depending on the stage and potential of the company.
What kind of support does LongRiver provide to its portfolio companies?
LongRiver adds value through its global resources, domain expertise, and cross-border business-development capabilities, supporting companies from sourcing through to exit.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.